Article Navigation
Article Contents
-
Abstract
- < Previous
- Next >
Journal Article
, Colin Watts University of Birmingham Search for other works by this author on: Oxford Academic Amit Patel Cancer Research UK Clinical Trials Unit, University of Birmingham Search for other works by this author on: Oxford Academic Joshua Savage Cancer Research UK Clinical Trials Unit, University of Birmingham Search for other works by this author on: Oxford Academic Olaf Ansorge University of Oxford Search for other works by this author on: Oxford Academic Victoria Wykes University of Birmingham Search for other works by this author on: Oxford Academic Yvonne Wallis Birmingham Women’s and Children’s NHS Foundation Trust Search for other works by this author on: Oxford Academic Rowena Sharpe Cancer Research UK Clinical Trials Unit, University of Birmingham Search for other works by this author on: Oxford Academic Rhys Mant Cancer Research UK Clinical Trials Unit, University of Birmingham Search for other works by this author on: Oxford Academic Hannah Brooks University of Oxford Search for other works by this author on: Oxford Academic Susan Short Leeds Teaching Hospitals NHS Trust Search for other works by this author on: Oxford Academic
, Keyoumars Ashkan King’s College London Search for other works by this author on: Oxford Academic Paul Brennan University of Edinburgh Search for other works by this author on: Oxford Academic Anthony Chalmers University of Glasgow Search for other works by this author on: Oxford Academic Stuart Smith Nottingham University Hospitals NHS Trust Search for other works by this author on: Oxford Academic Michael Jenkinson The Walton Centre NHS Foundation Trust Search for other works by this author on: Oxford Academic Catherine McBain The Christie NHS Foundation Trust Search for other works by this author on: Oxford Academic Adam Waldman University of Edinburgh Search for other works by this author on: Oxford Academic Gerard Thompson University of Edinburgh Search for other works by this author on: Oxford Academic Lucinda Billingham Cancer Research UK Clinical Trials Unit, University of Birmingham Search for other works by this author on: Oxford Academic
Neuro-Oncology, Volume 25, Issue Supplement_3, October 2023, Pages iii8–iii9, https://doi.org/10.1093/neuonc/noad147.035
Published:
16 September 2023
- Split View
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
Colin Watts, Amit Patel, Joshua Savage, Olaf Ansorge, Victoria Wykes, Yvonne Wallis, Rowena Sharpe, Rhys Mant, Hannah Brooks, Susan Short, Keyoumars Ashkan, Paul Brennan, Anthony Chalmers, Stuart Smith, Michael Jenkinson, Catherine McBain, Adam Waldman, Gerard Thompson, Lucinda Billingham, TESSA JOWELL BRAIN MATRIX PLATFORM STUDY: PRELIMINARY ANALYSIS OF THE PRIMARY FEASIBILITY & PROCESS-CENTRED OBJECTIVE, Neuro-Oncology, Volume 25, Issue Supplement_3, October 2023, Pages iii8–iii9, https://doi.org/10.1093/neuonc/noad147.035
Close
Search
Close
Search
Advanced Search
Search Menu
Abstract
AIMS
The Tessa Jowell BRAIN MATRIX (ISRCTN14218060) is an ongoing platform study, collecting disease, treatment, and outcome data prospectively in glioma patients, across nine UK hospitals. We report a preliminary analysis of the primary feasibility and process-centred objectives.
METHOD
Primary Objective: Test the feasibility of establishing an integrated histological-molecular diagnosis using Whole Genome Sequencing (WGS) and Epigenomic Classification (EC) (‘Heidelberg Classifier’) data in NHS practice within 28 days.
Primary Outcome: Time (from surgery) to integrated histological–molecular diagnosis (TTMD) using WGS and EC.
Secondary Outcome: Time to completion of each node (stage) of the tissue and imaging pathway.
RESULTS
Data snapshot on 23-Feb-2023 confirmed 250 patients recruited. Nine nodes along the tissue & imaging pathway were defined. Twenty-one patients had completed the pathway and time to each node was calculated. Median time to complete the pathway was 404 days (range 124-653). There was a trend of improvement in TTMD in recently recruited patients.
CONCLUSIONS
The patient pathway from surgery to clinical feedback through a Genomic Tumour Advisory Board (GTAB) utilises NHS-accredited pathways and protocols. Delays inherent in the pathway emphasise the urgent need for infrastructure and operational delivery improvements of the NHS Genomic Medicine Service for brain cancer patients as the current timeframe is not clinically relevant for informing patient care. These data also highlight geographical inequality in accessing genomic medicine within England, across the seven Genomic Laboratory Hubs, and the devolved nations. Detailed analysis of the delays at each node will identify opportunities and solutions to inform discussions with the NHS and Genomics England.
This content is only available as a PDF.
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
Topic:
- feedback
- genome
- genomics
- glioma
- objective (goal)
- molecular diagnostic techniques
- surgical procedures, operative
- brain
- diagnosis
- diagnostic imaging
- neoplasms
- surgery specialty
- genomic medicine
- national health service (uk)
- primary outcome measure
- whole genome sequencing
- epigenomics
- malignant brain neoplasms
Download all slides
Advertisement
Citations
Views
48
Altmetric
More metrics information
Metrics
Total Views 48
0 Pageviews
48 PDF Downloads
Since 9/1/2023
Month: | Total Views: |
---|---|
September 2023 | 8 |
October 2023 | 5 |
November 2023 | 5 |
December 2023 | 3 |
January 2024 | 5 |
February 2024 | 4 |
March 2024 | 6 |
April 2024 | 2 |
May 2024 | 2 |
June 2024 | 5 |
July 2024 | 3 |
Citations
Powered by Dimensions
Altmetrics
Email alerts
Article activity alert
Advance article alerts
New issue alert
Receive exclusive offers and updates from Oxford Academic
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons
Synaptic input to brain tumors: clinical implications
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review
Related articles in PubMed
Citing articles via
Google Scholar
-
Latest
-
Most Read
-
Most Cited
More from Oxford Academic
Clinical Medicine
Medical Oncology
Medicine and Health
Neurology
Books
Journals
Long Island, New York
Long Island, New York
Baltimore, Maryland
Brockville, Ontario
Advertisement